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inflexibly. We would argue that the SSRIs do have an important 
role to play in psychiatric practice, including that of child and 
adolescent psychiatry, and that clinicians should, as always, 
balance the benefits and risks for any particular patient and 
keep the interests of the patient paramount. Obtaining an 
expert opinion from a child and adolescent psychiatrist would 
be useful in situations where a practitioner is unsure.  We hope 
that the MCC will urgently reconsider the wording of this 
directive, in the interests of the many young patients who may 
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Rocephin – the thin end of the wedge 
To the Editor: I am sure I speak for many colleagues who have 
been cajoled, squeezed, begged and pressurised by medical 
aids, hospital administrators, pharmacists and representatives 
to stick to formularies to the point at which, backs against the 
wall, we say, ‘No more!’  The ‘thin edge of the wedge’ for me is 
the Rocephin issue.  
   I have grown up with Rocephin.  For me, rightly or wrongly, 
Rocephin is the drug that diminishes my anxiety, oh so slightly, 
over the safety of my patients; that may prevent meningitis 
secondary to sinus surgery; and that may stop a child’s 
otorrhoea when other drugs have failed and prevent him or her 
from developing mastoiditis.
   But despite evidence that many generics are inferior,1 the 
pressure is on me not to use Rocephin, but to prescribe a 
generic, for the vast saving of about R5 per dose.
   When will this pressure stop?  If I surrender on the Rocephin 
issue, what comes next? Are the medical aid administrators, 
the hospital managers and the pharmaceutical buyers willing 
to share the medical risk that I face on a daily basis?  Will 
they stand in the dock with me one day, and admit to using 
medications that are not proven to be equal in efficacy?
   We hear so much about ‘sharing risk’ nowadays. The best 
way those pressurising me to use ‘their’ not ‘my’ choice of 
drugs can share risk, is by sharing my risk.  What about, as 
a suggestion, paying all or part of my medical indemnity 
insurance?
   I’m not looking for handouts.  I’m not looking for perverse 
incentives.  I don’t even know, or care, whether the ‘local’ 
generic ceftriaxone is equivalent to Rocephin.  For a saving 
of only R5 a dose? I learn from one generic manufacturer that 
their local factory manufacturing quality is excellent, and then I 
hear that the drug I am interested in is allegedly manufactured 
in Turkey, shipped to Germany, and then to South Africa where 
it is distributed.
   For me there is a line I dare not cross, on the other side of 
which my autonomy stands for nothing.  Where I still have 
a choice, I must fight to maintain it, lest that thin edge of the 
wedge be pushed in further and further, until it becomes a 
thick edge, and then a wall.  ‘Rocephin’ for me is that issue, 
and I will not budge.  It is time we as a collective organisation 
of medical professionals stand up and say to those who would 
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Problematic childhood atopic eczema 
consensus document? 
To the Editor: The childhood atopic eczema consensus 
document published as part 2 of the June issue of the SAMJ1 is 
problematic and necessitates the following comments.
   A discussion of the controversy over the definition of atopic 
eczema is necessary, particularly in view of the recommen-
dations that pertain to allergy testing. Without this the rest of 
the article is open to misinterpretation. When dermatologists 
speak of atopic eczema they mean a clinical diagnosis. As 
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